Filtering by:
Targeted TherapyFDA Approves Rozlytrek (Entrectinib) for Tumors With Certain Genetic Markers
The US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for adults and adolescents with tumors that test positive for NTRK gene changes, which can help cancerous tumors grow.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
FDA Approves First PI3K Inhibitor for Breast Cancer
The US Food and Drug Administration (FDA) has approved the first treatment of its kind for a certain type of breast cancer caused by an inherited genetic mutation. Piqray (alpelisib) is a targeted therapy called a PI3K inhibitor.
FDA Approves First Targeted Therapy for Bladder Cancer
The US Food and Drug Administration (FDA) has approved Balversa (erdafitinib) as the first targeted therapy for bladder cancer.
2018 in Review: New Cancer Drug Approvals
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
New Drug Reduces Recurrence Risk for Some Women With Early-Stage Breast Cancer
Research presented at the San Antonio Breast Cancer Symposium may result in a new standard of care for some people with HER2 positive, early stage breast cancer.
FDA Approves 2 Drugs for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved 2 new drugs, Daurismo (glasdegib) and Venclexta (venetoclax), to treat people newly diagnosed with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.
FDA Approves Tibsovo (Ivosidenib) for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved the targeted therapy drug Tibsovo (ivosidenib) to treat some adults with a certain type of acute myeloid leukemia (AML).